Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13107175 | 0.93 | CYP2D6 (0.50) | CYP2D6HTR4KCNH2TLR7P2RY12 | |
| SCHEMBL13107197 | 0.93 | CYP2D6 (0.42) | CYP2D6HTR4KCNH2TLR7P2RY12 | |
| SCHEMBL13106687 | 0.92 | PDE2A (0.40) | CYP2D6TLR7GPBAR1CYSLTR2CYSLTR1 | |
| SCHEMBL13349781 | 0.92 | CYP2D6 (0.43) | CYP2D6HTR4KCNH2TLR7P2RY12 | |
| SCHEMBL13349856 | 0.91 | CYP2D6 (0.43) | CYP2D6HTR4KCNH2TLR7P2RY12 | |
| SCHEMBL13106246 | 0.91 | CYP2D6 (0.43) | CYP2D6HTR4KCNH2TLR7P2RY12 | |
| SCHEMBL13106256 | 0.90 | CYP2D6 (0.42) | CYP2D6HTR4KCNH2TLR7P2RY12 | |
| SCHEMBL13349838 | 0.90 | CYP2D6 (0.42) | CYP2D6HTR4KCNH2TLR7P2RY12 | |
| SCHEMBL13107270 | 0.90 | CYP2D6 (0.42) | CYP2D6HTR4KCNH2TLR7P2RY12 | |
| SCHEMBL13097063 | 0.89 | CYP2D6 (0.44) | CYP2D6HTR4KCNH2RIPK2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885HTR4 3056/4885KCNH2 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.